Short Summary
R‑Pac International seeks Director review after the PTAB denied institution of its IPR challenging Adasa’s RFID tag patent. The petitioner alleges the Board abused discretion by refusing a preliminary reply and misapplying prior‑art combinations.
Detailed Summary
In Petitioner's Request for Director Review (IPR2024‑01416), R‑Pac International Corporation challenges the PTAB's denial of institution for its inter partes review of Adasa Inc.'s RFID transponder patent (U.S. Patent No. 9,798,967). The petitioner contends the Board abused its discretion by refusing authorization for a preliminary reply on §325(d) grounds, by conducting sua sponte analysis not raised by either party, and by erroneously finding that the prior‑art references—RFID for Dummies, Traub, and EPC Tag Data Standards—were cumulative to a reexamination reference. Petitioner requests vacatur of the institution denial and a new decision with full briefing. The request is filed by lead counsel Jessica C. Kaiser, with Richard A. Wojcio, Jr. representing the patent owner.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in r-pac International Corporation vs Adasa Inc is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Google LLC et al.vsMullen Industries LLC
Google and Samsung’s petition to institute an IPR against Mullen Industries’ patent was denied. The Patent Owner’s response emphasized the Director’s discretionary authority, the parallel district‑court trial, and weak petition merits.
BOE Technology Group Co., Ltd.vsSamsung Display Co., Ltd.
BOE and Samsung have settled all disputes over U.S. Patent 11,081,503 and jointly moved to terminate the inter partes review. The motion cites compliance with 35 U.S.C. §317 and emphasizes public‑policy benefits of settlement.
Bonerge Lifescience (Hunan) Co., Ltd.vsNanjing Nutrabuilding Bio-Tech Co., Ltd.
Bonerge Lifescience petitions the PTAB to invalidate five method claims of a diabetes‑treatment patent, asserting obviousness over Turner, Shaw, Zhang and Feng references.
Citadel Securities LLCvsHFT Solutions, LLC
Citadel Securities petitions the PTAB to invalidate six claims of HFT Solutions’ ’286 patent, alleging that the FPGA‑PLL synchronization method is fully disclosed in Altera’s white paper, the Stratix Handbook, the Si5345 manual, and a 2012 Lockwood paper.
ZEPP HEALTH CORPORATIONvsWorcester Polytechnic Institute
Zepp Health filed an IPR against Worcester Polytechnic Institute’s patent 10,653,362. The parties settled the dispute before a trial, and the Board terminated the proceeding, keeping the settlement confidential.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.